RCUS
NYSEArcus Biosciences Inc.
News · 26 weeks47+20%
2026-03-012026-08-23
Mix2690d
- Insider12(46%)
- Other6(23%)
- SEC Filings6(23%)
- Earnings2(8%)
Latest news
25 items- INSIDERChief Accounting Officer Azoy Alexander exercised 2,827 shares at a strike of $15.44 and sold $84,810 worth of shares (2,827 units at $30.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
- PRArcus Biosciences Announces New Employment Inducement GrantsArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 2,850 shares of the Company’s common stock at an exercise price per share of $28.72, which was the closing price on August 10, 2026, and restricted stock units to acquire a total of 1,450 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Co
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Arcus Biosciences Inc.SCHEDULE 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)
- SECSEC Form 10-Q filed by Arcus Biosciences Inc.10-Q - Arcus Biosciences, Inc. (0001724521) (Filer)
- SECArcus Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Arcus Biosciences, Inc. (0001724521) (Filer)
- PRArcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline UpdateArcus executes on strategy to establish casdatifan as a backbone therapy across each line of treatment for clear cell renal cell carcinoma (ccRCC), including three new clinical trial collaborations that advance distinct casdatifan-based combinations New research published in Nature, evaluating patients with advanced ccRCC who were treated with casdatifan, provided the first data that comprehensively connect clinical outcomes for patients receiving a HIF-2α inhibitor with peripheral biomarker changes and associated tumor biology Multiple ARC-20 data readouts for casdatifan across lines of therapy are expected in the second half of 2026, including initial efficacy data for casdatif
- PRArcus Biosciences Announces New Employment Inducement GrantsArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 12,600 shares of the Company’s common stock at an exercise price per share of $29.73, which was the closing price on July 23, 2026, and restricted stock units to acquire a total of 6,300 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the
- PRArcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline UpdatesArcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will host a conference call and webcast on Wednesday, August 5th, 2026 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company’s financial results and pipeline updates for the quarter ended June 30th, 2026. Investors interested in listening to the conference call may do so by dialing +1 (585) 542-9983 (local) or +1 (833) 461-5787 (toll-free), using Meeting ID: 156828313. Participants may also register for the call online using the
- INSIDERPresident Jaen Juan C. sold $2,031,919 worth of shares (68,569 units at $29.63) as part of a pre-agreed trading plan (SEC Form 4)4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
- SECSEC Form 144 filed by Arcus Biosciences Inc.144 - Arcus Biosciences, Inc. (0001724521) (Subject)
- PRArcus Biosciences Announces New Employment Inducement GrantsArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employee options to purchase a total of 16,060 shares of the Company’s common stock at an exercise price per share of $30.26, which was the closing price on July 8, 2026, and restricted stock units to acquire a total of 8,080 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Comp
- SECSEC Form 144 filed by Arcus Biosciences Inc.144 - Arcus Biosciences, Inc. (0001724521) (Subject)
- INSIDERPresident Jaen Juan C. sold $877,501 worth of shares (31,431 units at $27.92) as part of a pre-agreed trading plan (SEC Form 4)4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
- PRArcus Biosciences Announces New Employment Inducement GrantsArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase a total of 18,400 shares of the Company’s common stock at an exercise price per share of $28.18, which was the closing price on June 23, 2026, and restricted stock units to acquire a total of 9,250 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Com
- SECSEC Form 144 filed by Arcus Biosciences Inc.144 - Arcus Biosciences, Inc. (0001724521) (Subject)
- INSIDERDirector Lambert Nicole was granted 5,700 shares, increasing direct ownership by 15% to 43,000 units (SEC Form 4)4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
- INSIDERDirector Kaneko Yasunori was granted 5,700 shares, increasing direct ownership by 28% to 25,700 units (SEC Form 4)4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
- INSIDERDirector Machado Patrick was granted 5,700 shares, increasing direct ownership by 15% to 44,300 units (SEC Form 4)4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
- INSIDERGeneral Counsel Tang Carolyn C. exercised 34,090 shares at a strike of $2.57, increasing direct ownership by 23% to 184,607 units (SEC Form 4)4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
- INSIDERDirector Lacey David L. was granted 5,700 shares, increasing direct ownership by 8% to 76,652 units (SEC Form 4)4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
- INSIDERDirector Ribas Antoni was granted 5,700 shares, increasing direct ownership by 15% to 44,300 units (SEC Form 4)4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
- INSIDERDirector Perlman Andrew J was granted 5,700 shares, increasing direct ownership by 13% to 48,325 units (SEC Form 4)4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
- INSIDERDirector Falberg Kathryn E was granted 5,700 shares, increasing direct ownership by 15% to 44,300 units (SEC Form 4)4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
- SECArcus Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Arcus Biosciences, Inc. (0001724521) (Filer)
- PRArcus Biosciences Announces New Employment Inducement GrantsArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 2,850 shares of the Company's common stock at an exercise price per share of $23.32, which was the closing price on June 8, 2026, and restricted stock units to acquire a total of 1,450 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Compa
RCUS FAQ
7 questionsWhat does Arcus Biosciences Inc. do?
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company is also developing Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; and AB680...Where does RCUS stock trade?
Arcus Biosciences Inc. (RCUS) is listed on NYSE.What sector and industry is RCUS in?
Arcus Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Arcus Biosciences Inc. go public?
Arcus Biosciences Inc. (RCUS) completed its IPO in 2018.What are analysts saying about RCUS?
Arcus Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from Truist: Buy with a $3500.00 price target on 2026-05-18. Recent price targets range from $2000.00 to $3500.00.What companies are similar to RCUS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare RCUS side-by-side with any of them on Quantisnow.How can I track RCUS on Quantisnow?
Quantisnow aggregates Arcus Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RCUS to receive live email and push alerts on every new disclosure.